James W. Janetka - Search Results

Year	Number of Results
2003	2
2007	2
2008	3
2009	2
2010	2
2011	2
2012	4
2013	1
2014	1
2015	1
2016	5
2017	6
2018	5
2019	7
2020	2
2021	6
2022	1
2024	6

1

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.

Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ. Spaulding CN, et al. Among authors: janetka jw. Nature. 2017 Jun 22;546(7659):528-532. doi: 10.1038/nature22972. Epub 2017 Jun 14. Nature. 2017. PMID: 28614296 Free PMC article.

2

Aspartyl Protease Inhibitors as Anti-Filarial Drugs.

Beld L, Jung H, Bulman CA, Rosa BA, Fischer PU, Janetka JW, Lustigman S, Sakanari JA, Mitreva M. Beld L, et al. Among authors: janetka jw. Pathogens. 2022 Jun 18;11(6):707. doi: 10.3390/pathogens11060707. Pathogens. 2022. PMID: 35745561 Free PMC article.

3

Precision antimicrobial therapeutics: the path of least resistance?

Spaulding CN, Klein RD, Schreiber HL 4th, Janetka JW, Hultgren SJ. Spaulding CN, et al. Among authors: janetka jw. NPJ Biofilms Microbiomes. 2018 Feb 27;4:4. doi: 10.1038/s41522-018-0048-3. eCollection 2018. NPJ Biofilms Microbiomes. 2018. PMID: 29507749 Free PMC article. Review.

4

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases.

Damalanka VC, Banas V, De Bona P, Kashipathy MM, Battaile K, Lovell S, Janetka JW. Damalanka VC, et al. Among authors: janetka jw. J Med Chem. 2024 Mar 28;67(6):4833-4854. doi: 10.1021/acs.jmedchem.3c02388. Epub 2024 Mar 13. J Med Chem. 2024. PMID: 38477709

5

Novel approaches to glycomimetic design: development of small molecular weight lectin antagonists.

Damalanka VC, Maddirala AR, Janetka JW. Damalanka VC, et al. Among authors: janetka jw. Expert Opin Drug Discov. 2021 May;16(5):513-536. doi: 10.1080/17460441.2021.1857721. Epub 2021 Feb 5. Expert Opin Drug Discov. 2021. PMID: 33337918 Review.

6

Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.

Damalanka VC, Janetka JW. Damalanka VC, et al. Among authors: janetka jw. Future Med Chem. 2019 Apr;11(7):743-769. doi: 10.4155/fmc-2018-0446. Epub 2019 Apr 4. Future Med Chem. 2019. PMID: 30945556 Review.

7

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

Ma CX, Janetka JW, Piwnica-Worms H. Ma CX, et al. Among authors: janetka jw. Trends Mol Med. 2011 Feb;17(2):88-96. doi: 10.1016/j.molmed.2010.10.009. Epub 2010 Nov 17. Trends Mol Med. 2011. PMID: 21087899 Free PMC article. Review.

8

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Mydock-McGrane LK, Hannan TJ, Janetka JW. Mydock-McGrane LK, et al. Among authors: janetka jw. Expert Opin Drug Discov. 2017 Jul;12(7):711-731. doi: 10.1080/17460441.2017.1331216. Epub 2017 Jun 2. Expert Opin Drug Discov. 2017. PMID: 28506090 Free PMC article. Review.

9

Checkpoint kinase inhibitors: a review of the patent literature.

Janetka JW, Ashwell S. Janetka JW, et al. Expert Opin Ther Pat. 2009 Feb;19(2):165-97. doi: 10.1517/13543770802653622. Expert Opin Ther Pat. 2009. PMID: 19441917 Review.

10

Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.

Mydock-McGrane LK, Cusumano ZT, Janetka JW. Mydock-McGrane LK, et al. Among authors: janetka jw. Expert Opin Ther Pat. 2016;26(2):175-97. doi: 10.1517/13543776.2016.1131266. Epub 2016 Jan 22. Expert Opin Ther Pat. 2016. PMID: 26651364 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

56 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year